Loading data
HUMANasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.04 m USD | 0 USD | — | — | — |
| Cost of revenue | 9.7 m USD | 0 USD | — | — | — |
| Research and development expense | 69.3 m USD | 88.6 m USD | 76.55 m USD | 63.26 m USD | 61.34 m USD |
| Operating profit | -108.1 m USD | -114.4 m USD | -100.05 m USD | -84.6 m USD | -81.21 m USD |
| Interest expense | — | — | 6.6 m USD | 6.2 m USD | 4.35 m USD |
| Profit before tax | -40.83 m USD | — | — | — | — |
| Income tax expense | 0 USD | 0 USD | 0 USD | 0 USD | 0 USD |
| Net income (reported basis) | -40.83 m USD | -148.7 m USD | -110.78 m USD | -11.97 m USD | -26.48 m USD |
| Basic earnings per share | -0.26 USD/share | -1.26 USD/share | -1.07 USD/share | -0.12 USD/share | -0.66 USD/share |
| Diluted earnings per share | -0.26 USD/share | -1.26 USD/share | -1.07 USD/share | -0.12 USD/share | -0.66 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.